This study is an attempt to produce gadolinium-doped iron oxide nanoparticles for the purpose of utilization in magnetic fluid hyperthermia (MFH). Six gadolinium-doped iron oxide samples with varying gadolinium contents ( were prepared using the hydrothermal method and high vapor pressure to incorporate gadolinium ions in the iron oxide structure. The samples were indexed as , with varying from 0.0 to 0.1. The results reveal that gadolinium ions have a low solubility limit in the iron oxide lattice (x = 0.04). The addition of gadolinium caused distortion in the produced maghemite phase and formation of other phases. Based on X-ray diffraction (XRD) analysis and photoelectron spectroscopy (XPS), it was observed that gadolinium mostly crystalized as gadolinium hydroxide, for gadolinium concentrations above the solubility limit. The measured magnetization values are consistent with the formed phases. The saturation magnetization values for all gadolinium-doped samples are lower than the undoped sample. The specific absorption rate (SAR) for the pure iron oxide samples was measured. Sample GdIO/0.04, pure iron oxide doped with gadolinium, showed the highest potential to produce heat at a frequency of 198 kHz. Therefore, the sample is considered to hold great promise as an MFH agent.

No abstract

<abstract> <p>The current study presents a bimodal therapeutic platform for cancer treatment. Bimodal implies that the presented drug loaded core-shell structure is capable of elevating the tumor tissue temperature (hyperthermia) through the superparamagnetic iron oxide core and simultaneously release a Poly (ADP-ribose) polymerase-1(PARP-1)-modifying agent from the thermoresponsive shell. Magnetic thermoresponsive nanocomposite MTN was synthesized via an in situ free radical polymerization of thermo-responsive (N-isopropylacrylamide) (NIPAAm) monomer in the presence of 11-nm monodisperse SPIONs. The composite was allowed to swell in various concentrations of the PARP inhibitor: 5-aminoisoquinoline (5-AIQ) forming drug-loaded magnetic thermoresponsive nanocomposite (MTN-5.AIQ). Structural characterization of the formed composite is studied via various experimental tools. To assess the coil to globule transition temperature, the lower critical solution temperature (LCST) is determined by differential scanning calorimetry (DSC) method and the cloud point (Tp) is determined by turbidometry. Magnetic thermoresponsive nanocomposite (MTN) is formed with excellent potential for hyperthermia. A high drug loading efficiency (85.72%) is obtained with convenient temperature dependent drug release kinetics. Biocompatibility and cytotoxic efficacy are tested on an in vivo and in vitro colorectal-adenocarcinoma model, respectively. MTN.5-AIQ administration exhibits normal hepatic and renal functions as well as lower toxic effect on normal tissue. In addition, the composite effectively inhibits Caco-2 cells viability upon incubation. Based on the obtained results, the proposed therapeutic platform can be considered as a novel, promising candidate for dual therapy of colorectal adenocarcinoma exhibiting a PARP-1 overexpression. as well as increased the inhabiting efficacy of 5-AIQ.</p> </abstract>

No abstract